720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial

Johann De Bono, Stephane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude de Gassart, Emmanuel Valentin, Marina Iche, Maelle Mairesse, Patrick Brune, Daniel Olive, Paul Frohna

Open source

DOI: 10.1136/jitc-2022-sitc2022.0720
Published: 2022-11
Container: Regular and Young Investigator Award Abstracts
Publisher: BMJ Publishing Group Ltd
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-sitc2022.0720,
  title = {720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial},
  author = {Johann De Bono and Stephane Champiat and Francois-Xavier Danlos and Martin Wermke and Volker Kunzmann and Aude de Gassart and Emmanuel Valentin and Marina Iche and Maelle Mairesse and Patrick Brune and Daniel Olive and Paul Frohna},
  year = {2022},
  journal = {Regular and Young Investigator Award Abstracts},
  doi = {10.1136/jitc-2022-sitc2022.0720},
  url = {https://doi.org/10.1136/jitc-2022-sitc2022.0720}
}

RIS

TY  - JOUR
TI  - 720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial
AU  - Johann De Bono
AU  - Stephane Champiat
AU  - Francois-Xavier Danlos
AU  - Martin Wermke
AU  - Volker Kunzmann
AU  - Aude de Gassart
AU  - Emmanuel Valentin
AU  - Marina Iche
AU  - Maelle Mairesse
AU  - Patrick Brune
AU  - Daniel Olive
AU  - Paul Frohna
PY  - 2022
JO  - Regular and Young Investigator Award Abstracts
DO  - 10.1136/jitc-2022-sitc2022.0720
UR  - https://doi.org/10.1136/jitc-2022-sitc2022.0720
ER  -

APA

Bono, J. D., Champiat, S., Danlos, F., Wermke, M., Kunzmann, V., Gassart, A. D., Valentin, E., Iche, M., Mairesse, M., Brune, P., Olive, D., & Frohna, P. (2022). 720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2022-sitc2022.0720

Source records

crossref · retrieved 2026-11-08T18:29:19.131Z